Articles On Cyclopharm (ASX:CYC)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX stumbles as announcement outage leaves traders scrambling to catch up Gold and oil climb, providing some support in energy and resource stocks Wall Street futures weigh heavy; market falls 0.57% ASX scrambles to address announcement b...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX climbs +0.23% before falling -0.25% Losses in banks, utilities, info tech undercut recovery Energy, materials, real estate mount resistance Markets wobble into red The ASX 200 obviously hasn’t quite recovered from the beating it took...

Ahead of EBR Systems’ official Wise launch in the US, clinicians already have implanted a dozen patients with the heart device Renerve shares more than double on key US nerve repair military approval   Cynata enters “the most important” ch...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Healthcare stocks are often labelled as "underrepresented" on the Australian stock market.  That's because compared to other sectors like financials (big banks) and resources (mining and energy), healthcare makes up a much smaller portio...

Little Green Pharma reports record revenue and a return to profits Botanix raises $48 million of debt for its anti-sweating drug, Sofdra The DNA of Genetic Technologies soon will be … financial advice   Little Green Pharma’s (ASX:LGP) Eur...

Cyclopharm (ASX: CYC) has gained further momentum in its strategy to grow sales of its Technegas kit in the US after being granted an extension to its patent there. The new United States Patent and Trademark Office (USPTO) approval provides...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 poised for a positive open, reflecting cautious optimism amid global economic signals Firms such as ASX:ACR, ASX:CYC, and ASX:BBT show strong internal alignment and anticipated growth Sectoral growth expec...

Highlights ASX 200 sees upward momentum driven by IT and Financials, with Real Estate and Energy trailing. Noteworthy companies with high internal stakes show consistent revenue growth across varied sectors. Companies like A...

Highlights ASX200 experiences a minor dip, while Energy and Real Estate sectors advance. Several ASX-listed growth companies show robust earnings growth. High earnings growth observed across selected industrial and mining fi...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Universal Biosensors (ASX:UBI) is well into commercial phase and is thus ‘grown up’, but chairman Graham McLean acknowledges the company has struggled to reach adulthood and produce consistent returns. “Progress has always been slower than...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

Highlights: Several ASX-listed companies have demonstrated high earnings expansion alongside substantial ownership from internal stakeholders. Businesses spanning sectors such as minerals, biotechnology, and consumer services exh...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

In a dour end to what’s been a red-washed Week 11, early morning ASX 200 futures are pointing to a 0.2% decline – to around 7,734 points today – after Trump’s trade war found a fiery new battleground: Global alcohol sales. Listen to the...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Australia’s S&P/ASX 200 fell 3.79% in February as global geopolitical and economic uncertainties rattled markets Only four out of 11 S&P/ASX 200 sectors posted gains, primarily driven by defensive sectors Kalgoorlie Gold Mining was...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AHI)) - Advan...

ASX down, hits six losses in seven days Johns Lyng, Domino’s and Viva Energy hit hard Zip shines bright, while gold flirts with record highs   The ASX200 closed 0.7% lower on Tuesday, bringing its record to six losses in seven days. Today...

Polynovo and Avita Medical are victims of skittish market behaviour Cyclopharm breathes easier after a good start with US sales Control Bionics raises $2 million to rev up commercialisation   Investor reaction to PolyNovo’s (ASX:PNV) half...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Radiopharmaceutical company Cyclopharm (ASX: CYC) has signed a contract to deploy its flagship product Technegas in as many as 169 nuclear medicine departments across the Hospital Corporation of America Healthcare (HCA) suite of facilities....

Although under pressure today, the All Ordinaries Index (ASX: XAO) is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains. At market close yesterday, these three companies were leading the charge higher in...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX flat despite tech rally Uranium miners gain further after Cameco suspends production Canada’s PM Justin Trudeau set to resign amid mounting pressure   The ASX closed flattish on Monday despite a tech rally. The tech sector rose follow...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Opyl has partnered to form the ‘world’s first’ AI-driven biotech fund Visioneering sees a brighter future – elsewhere – but its shares tumble  Cyclopharm breathes easy after decent lung transplant trial results   Who needs fund managers t...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Invion enrols its first patient in its Queensland skin cancer study Inoviq says it has the clinical proof to commercialise its early-stage ovarian cancer detection test Are we on the cusp of Trump-driven US healthcare M&A fiesta?   I...

Cyclopharm (ASX:CYC) has dosed its first French patients with its technegas lung imaging product in an ongoing trial. While the company received FDA approval in the U.S. last year, the company is conducting its ‘PRONOSPECT’ trial across 13...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow   It’s not th...

There have been some big moves in the healthcare sector on Thursday. For example, the two ASX healthcare shares listed below are up at least 16% in morning trade thanks to big news in the United States. Here's what you need to know about th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Noxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell growth in preclinical models. Percheron Therapeutics announces “very encouraging” new data for its epilepsy program Cyclopharm is off to a soli...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck Welcome to the FNArena Corporate Results Monitor. Today's Reports:...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below. They have just been tipped as Bell Potter's top healthcare stocks to buy now: Aroa Biosurgery Ltd (ASX: ARX) Aroa Biosu...